Vedic, Amarex Collaborating on Research

MUMBAI, India & GERMANTOWN, Md.—Vedic Lifesciences and Amarex LLC (AmarexCRO.com) signed an agreement to collaborate on clinical development and regulatory affairs services for botanical drugs in the United States and India. According to Jayesh Chaudhary, CEO of India-based Vedic Lifesciences (www.VedicLifesciences.com), the company had completed more than two dozen studies on active compounds in recent years, and “the agreement with Amarex greatly enhances Vedic’s access to the U.S. market and elsewhere outside Asia.” Mukesh Kumar, head of safety and regulatory affairs at Amarex, added: “Amarex’s growing involvement with botanical drug development is a good fit with Vedic’s special expertise with such compounds. It is clear that having an Asian partner will provide certain advantages to our clients’ drug development needs.”